A team of experts dedicated to identifying, developing and commercializing novel cancer therapeutics A diversified portfolio of innovative cancer compounds in preclinical and clinical development Three products in advanced development, each representing a major therapeutic and commercial opportunity Adherex is focused on developing solutions to unmet needs in cancer Long-term complications Treatment resistance and debilitating side effects
Missing: Adherex's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Adherex's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Adherex
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Adherex is included in 2 Expert Collections, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Adherex has filed 1 patent.
Prodrugs, Organofluorides, Designer drugs, Abandoned drugs, Carbamates
Prodrugs, Organofluorides, Designer drugs, Abandoned drugs, Carbamates
Latest Adherex News
Oct 20, 2015
, is 100 per cent biodegradable. The environmentally safe formula is non-toxic to marine life and not a hazardous substance. Menteri Besar Datuk Seri Adnan Yaakob said the new technique was more effective and economical compared with the existing method, which was to use high-pressure water to wash roads to prevent dust being blown around. He said if Adherex 120 received the green light, bauxite-mining operators would have to shoulder the cost for the product and use it. "We cannot blame the authorities but we will work together to overcome the problems. "The state government will continue looking into other measures, including special sacks, to minimise pollution," he said at a briefing on Adherex 120 at the Land and Mines office yesterday, The briefing, attended by executive council members, assemblymen, department heads and the media, was conducted by Kam Biotechnology Ltd chief executive officer and Scientific Board chairman Professor Mongi Ferchichi
Adherex Frequently Asked Questions (FAQ)
When was Adherex founded?
Adherex was founded in 1996.
Where is Adherex's headquarters?
Adherex's headquarters is located at 4620 Creekstone Drive, Durham.
What is Adherex's latest funding round?
Adherex's latest funding round is Unattributed VC - V.
How much did Adherex raise?
Adherex raised a total of $39.48M.
Who are the investors of Adherex?
Investors of Adherex include OrbiMed Advisors, GSK, VenGrowth Capital Partners, Hotung Investment Holdings, Dalton Strategic Partnership and 6 more.
Who are Adherex's competitors?
Competitors of Adherex include Endocyte, Pique Therapeutics, Raptor Pharmaceutical Corp., ProCertus BioPharm, YM BioSciences and 11 more.
Compare Adherex to Competitors
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.
Argenes, Inc. is a Japanese bio-venture established in April 2004 focusing primarily on the development of biopharmaceuticals and molecular targeting therapeutics, including anti-rheumatoid arthritis (RA), and anti-osteoarthritis. Currently, the company's most innovatory prospective candidate for the treatment of RA is the drug anti-Fas mAb ARG098. The company operate preclinical and clinical studies as well as manufacturer pharmaceuticals through managing of CRO and CMO. At Argenes, Inc. the company continually seek to expand globally through creating alliances and through licensing out development rights and marketing rights.
Amrita Therapeutics develops drugs that combat public health threats of the 21st century with fewer side-effects and at an cost. Amrita Therapeutics therapies and cures will treat cervical cancer, CNS disorders, HIV/AIDS, malaria and/or tuberculosis by designing the products of bacteria to defend the human body against more than one disease simultaneously, utilizing or interfering in multiple pathways or mechanisms.
Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.